ReviewFrontiers in cellular neuroscience2014
The 5-lipoxygenase pathway: oxidative and inflammatory contributions to the Alzheimer's disease phenotype.
Review in Frontiers in cellular neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Tea tree oil, a vibrant source of neuroprotection via neuroinflammation inhibition: a critical insight into repurposingJournal of Zhejiang University. Science. B · 2023Pooled it
- Nutritional Mushroom Treatment in Meniere's Disease withInternational journal of molecular sciences · 2019Trial
- The Substrate-Engine Model of Ferroptosis: Stage-Specific Targeting of Acyl-CoA Synthetase Long-Chain Family Member 4 and 5‑Lipoxygenase in Alzheimer's Disease.ACS pharmacology & translational science · 2026Review
- Ferroptosis-related stress during aging and its relevance to disease.GeroScience · 2026Review
- Differential Regulation of Inflammatory and Pro-Resolving Lipid Mediators in Chronic Coronary Syndrome Across Cardiometabolic Phenotypes.International journal of molecular sciences · 2026Observational
- Transcriptomic signatures of oxytosis/ferroptosis are enriched in Alzheimer's disease.BMC biology · 2025Article
- Multifaceted Biological Activities of Culinary Herb and Spice Extracts: In Vitro and In Silico Simulation Insights into Inflammation-Related Targets.Foods (Basel, Switzerland) · 2025Article
- Multipotent Effect of Clozapine on Lipopolysaccharide-Induced Acetylcholinesterase, Cyclooxygenase-2,5-Lipoxygenase, and Caspase-3: In Vivo and Molecular Modeling Studies.Molecules (Basel, Switzerland) · 2025Article
- The Role of AMP-activated Protein Kinase in Oxytosis/Ferroptosis: Protector or Potentiator?Antioxidants & redox signaling · 2024Review
- ¹H-NMR Metabolic Profiling, Antioxidant Activity, and Docking Study of Common Medicinal Plant-Derived Honey.Antioxidants (Basel, Switzerland) · 2022Article
- Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators-What is the Evidence so far?Frontiers in pharmacology · 2022Review
- The search for anti-oxytotic/ferroptotic compounds in the plant world.British journal of pharmacology · 2021Review
- The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Downregulation of autophagy by 12/15Lipoxygenase worsens the phenotype of an Alzheimer's disease mouse model with plaques, tangles, and memory impairments.Molecular psychiatry · 2021Article
- Inflammation Drives Alzheimer's Disease: Emphasis on 5-lipoxygenase Pathways.Current neuropharmacology · 2021Review
- Using the Oxytosis/Ferroptosis Pathway to Understand and Treat Age-Associated Neurodegenerative Diseases.Cell chemical biology · 2020Review
- The Δ133p53 Isoforms, Tuners of the p53 Pathway.Cancers · 2020Review
- Hybridization of Curcumin Analogues with Cinnamic Acid Derivatives as Multi-Target Agents Against Alzheimer's Disease Targets.Molecules (Basel, Switzerland) · 2020Article
- Antagonism of cysteinyl leukotrienes and their receptors as a neuroinflammatory target in Alzheimer's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Review
- 16HBE Cell Lipid Mediator Responses to Mono and Co-Infections with Respiratory Pathogens.Metabolites · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most common, and, arguably, one of the most-well studied, neurodegenerative conditions. Several decades of investigation have revealed that amyloid-β and tau proteins are critical pathological players in this condition. Genetic analyses have revealed specific mutations in the cellular machinery that produces amyloid-β, but these mutations are found in only a small fraction of patients with the early-onset variant of AD. In addition to development of amyloid-β and tau pathology, oxidative damage and inflammation are consistently found in the brains of these patients. The 5-lipoxygenase protein enzyme (5LO) and its downstream leukotriene metabolites have long been known to be important modulators of oxidation and inflammation in other disease states. Recent in vivo evidence using murine knock-out models has implicated the 5LO pathway, which also requires the 5LO activating protein (FLAP), in the molecular pathology of AD, including the metabolism of amyloid-β and tau. In this manuscript, we will provide an overview of 5LO and FLAP, discussing their involvement in biochemical pathways relevant to AD pathogenesis. We will also discuss how the 5LO pathway contributes to the molecular and behavioral insults seen in AD and provide an assessment of how targeting these proteins could lead to therapeutics relevant not only for AD, but also other related neurodegenerative conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.